The video provides an analysis of Enanta Pharmaceuticals stock, updated as of September 28, 2025. Stock score data from September 26, 2025, assigned a hold or accumulate rank to Enanta Pharmaceuticals with a score of -0.108. Current assessment reveals the stock is positioned within a rising trend in the short term. Potential change of approximately 12.4% may be seen in the next three months, returns between 2.71% and 31.62%. The 12-month analysis predicts a projected change of -20.6%. The stock's price could fluctuate between negative 67.90% and negative 10.35% over the coming year. Trading volume increased on the last day. Fibonacci and Accumulated Volume support and resistance levels are given, with the support at $7.81 and resistance at $8.39. It has a weekly volatility of 7.31%. Capps Kathleen bought and sold 16115 shares in the company. It has a P/E ratio of -1.83 with a suggested stop-loss at $7.57.